Clinical Trials

20 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07402343 2026-03-04

T-BRAIN

34 enrolled

Brain Neoplasms, Small Cell Lung Carcinoma

NCT07449481 2026-03-04

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

56 enrolled

Brain Neoplasms

NCT04298541 2026-02-27

Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

6 enrolled

Meningioma

NCT07439172 2026-02-27

PRC

70 enrolled

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT07428616 2026-02-24

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

100 enrolled

Brain Neoplasms, Meningioma

NCT07424092 2026-02-20

PED-DNX2401

39 enrolled

Ependymoma, Glioma, Recurrence

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

41 enrolled

CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT07383649 2026-02-03

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

28 enrolled

Brain Neoplasms

NCT07356973 2026-01-26

OPTICAL

147 enrolled

Glioblastoma

NCT07365280 2026-01-26

Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

78 enrolled

Glioblastoma

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06907485 2026-01-21

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

20 enrolled

Brain Neoplasms

NCT07347210 2026-01-16

MATVAC-1

98 enrolled

Primary Glioblastoma

NCT07343479 2026-01-15

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

45 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06858501 2025-12-31

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

84 enrolled

Ganglioneuroblastoma

NCT07284628 2025-12-16

ReVoGlio

78 enrolled

Glioblastoma

NCT07261241 2025-12-03

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

118 enrolled

Neuroblastoma

NCT07206849 2025-10-29

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

79 enrolled

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Glioma

NCT06804655 2025-10-02

EViDENCE-BT

40 enrolled

Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Neurologic Manifestations

NCT07197008 2025-09-29

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

50 enrolled

Brain Neoplasms, Lung Neoplasms

NCT06492486 2025-09-16

GLADIATOR

Glioblastoma

NCT07111117 2025-09-03

NEUROBLASTOTEP

30 enrolled

Neuroblastoma

NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

Glioblastoma

NCT07120984 2025-08-13

IMAGLIO

52 enrolled

Glioma

NCT01777919 2025-05-25

GLIODIS

32 enrolled

Glioblastoma

NCT06974370 2025-05-15

ACTION-Brain

45 enrolled

Brain Neoplasms

NCT06971406 2025-05-14

FLAME-1

100 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06894225 2025-04-06

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

12 enrolled

Glioblastoma

NCT06678867 2025-03-27

P5A

80 enrolled

Brain Neoplasms, Ependymoma, Glioma

NCT06780592 2025-01-22

Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

Glioblastoma

NCT06763315 2025-01-08

LS-NF1PNs

50 enrolled

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06620354 2024-10-01

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

33 enrolled

Neurofibromatosis 1

NCT06621082 2024-10-01

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

19 enrolled

Neurofibromatosis 1

NCT06483672 2024-07-03

LungBrain001

27 enrolled

Adenocarcinoma of Lung, Brain Neoplasms

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

43 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

112 enrolled

Meningeal Carcinomatosis

NCT05805631 2024-05-01

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

23 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

28 enrolled

Brain Neoplasms

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

255 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06218524 2024-01-23

The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

200 enrolled

Glioblastoma

NCT06210438 2024-01-18

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

24 enrolled

Brain Neoplasms

NCT05820191 2023-12-21

B-amyloid as a Marker for GBM Bioimaging

3 enrolled

Glioblastoma

NCT06088056 2023-10-18

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

17 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

30 enrolled

Glioblastoma

NCT05842746 2023-05-06

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

74 enrolled

Glioblastoma

NCT05502991 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

NCT05303727 2022-07-01

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

64 enrolled

Neuroblastoma

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

28 enrolled